Skip to main content

Peer Review reports

From: Lower starting dose of afatinib for the treatment of metastatic lung adenocarcinoma harboring exon 21 and exon 19 mutations

Original Submission
23 Sep 2020 Submitted Original manuscript
2 Jan 2021 Reviewed Reviewer Report
28 Feb 2021 Reviewed Reviewer Report
5 Apr 2021 Author responded Author comments - Yi-Chieh Chen
Resubmission - Version 2
5 Apr 2021 Submitted Manuscript version 2
8 Apr 2021 Reviewed Reviewer Report
19 Apr 2021 Author responded Author comments - Yi-Chieh Chen
Resubmission - Version 3
19 Apr 2021 Submitted Manuscript version 3
Publishing
22 Apr 2021 Editorially accepted
3 May 2021 Article published 10.1186/s12885-021-08235-3

You can find further information about peer review here.

Back to article page